Seon-Min Lee, Jieun Shin, Do-Young Kwon, Yu Jin Jung
{"title":"帕金森病患者潜在的不当用药:韩国国民健康保险索赔数据分析","authors":"Seon-Min Lee, Jieun Shin, Do-Young Kwon, Yu Jin Jung","doi":"10.3988/jcn.2025.0122","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Polypharmacy is common in Parkinson's disease (PD). This includes appropriate medications for PD-related symptoms and comorbid conditions, but also potentially inappropriate medications (PIMs). We aimed to determine the prescribing trends of PIMs based on the 2019 Beers Criteria in Korean patients with PD.</p><p><strong>Methods: </strong>This retrospective observational study analyzed PD patients aged 40 years or older whose PIM prescribing patterns from 2014 to 2019 were included in the HIRA (Korean Health Insurance Review and Assessment Service) nationwide claims database in South Korea. The prevalence and usage were analyzed for both overall PIMs and PIMs that can exacerbate PD symptoms (PIM<sup>PD</sup>s). Additionally, the most frequently prescribed PIMs and PIM<sup>PD</sup>s were investigated.</p><p><strong>Results: </strong>PIMs were used at least once in 38.3% of 257,142 patients with PD. The mean number of PIM items used per patient was 2.61. The PIM usage ratio, corresponding to the proportion of the total amount of PIMs to all medications per patient, was 19.7%. The proportion of patients taking PIMs among all PD patients decreased significantly up to 2018 but then increased in 2019, while the PIM usage ratio increased steadily up to 2018 and then decreased in 2019. Excluding the representative PD medications, the most frequently prescribed PIM was amitriptyline. PIM<sup>PD</sup>s were also commonly used, including levosulpiride and haloperidol.</p><p><strong>Conclusions: </strong>The prevalence and usage of PIMs were high in Korean PD patients during 2014-2019, and the utilization of PIM<sup>PD</sup>s persisted throughout this period. These findings can be used to develop evidence-based guidelines for robust polypharmacy management strategies to ensure the safety of medications used by PD patients.</p>","PeriodicalId":15432,"journal":{"name":"Journal of Clinical Neurology","volume":"21 5","pages":"405-414"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411295/pdf/","citationCount":"0","resultStr":"{\"title\":\"Potentially Inappropriate Medication Use in Patients With Parkinson's Disease: Analysis of Korean National Health Insurance Claims Data.\",\"authors\":\"Seon-Min Lee, Jieun Shin, Do-Young Kwon, Yu Jin Jung\",\"doi\":\"10.3988/jcn.2025.0122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and purpose: </strong>Polypharmacy is common in Parkinson's disease (PD). This includes appropriate medications for PD-related symptoms and comorbid conditions, but also potentially inappropriate medications (PIMs). We aimed to determine the prescribing trends of PIMs based on the 2019 Beers Criteria in Korean patients with PD.</p><p><strong>Methods: </strong>This retrospective observational study analyzed PD patients aged 40 years or older whose PIM prescribing patterns from 2014 to 2019 were included in the HIRA (Korean Health Insurance Review and Assessment Service) nationwide claims database in South Korea. The prevalence and usage were analyzed for both overall PIMs and PIMs that can exacerbate PD symptoms (PIM<sup>PD</sup>s). Additionally, the most frequently prescribed PIMs and PIM<sup>PD</sup>s were investigated.</p><p><strong>Results: </strong>PIMs were used at least once in 38.3% of 257,142 patients with PD. The mean number of PIM items used per patient was 2.61. The PIM usage ratio, corresponding to the proportion of the total amount of PIMs to all medications per patient, was 19.7%. The proportion of patients taking PIMs among all PD patients decreased significantly up to 2018 but then increased in 2019, while the PIM usage ratio increased steadily up to 2018 and then decreased in 2019. Excluding the representative PD medications, the most frequently prescribed PIM was amitriptyline. PIM<sup>PD</sup>s were also commonly used, including levosulpiride and haloperidol.</p><p><strong>Conclusions: </strong>The prevalence and usage of PIMs were high in Korean PD patients during 2014-2019, and the utilization of PIM<sup>PD</sup>s persisted throughout this period. These findings can be used to develop evidence-based guidelines for robust polypharmacy management strategies to ensure the safety of medications used by PD patients.</p>\",\"PeriodicalId\":15432,\"journal\":{\"name\":\"Journal of Clinical Neurology\",\"volume\":\"21 5\",\"pages\":\"405-414\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411295/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3988/jcn.2025.0122\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3988/jcn.2025.0122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Potentially Inappropriate Medication Use in Patients With Parkinson's Disease: Analysis of Korean National Health Insurance Claims Data.
Background and purpose: Polypharmacy is common in Parkinson's disease (PD). This includes appropriate medications for PD-related symptoms and comorbid conditions, but also potentially inappropriate medications (PIMs). We aimed to determine the prescribing trends of PIMs based on the 2019 Beers Criteria in Korean patients with PD.
Methods: This retrospective observational study analyzed PD patients aged 40 years or older whose PIM prescribing patterns from 2014 to 2019 were included in the HIRA (Korean Health Insurance Review and Assessment Service) nationwide claims database in South Korea. The prevalence and usage were analyzed for both overall PIMs and PIMs that can exacerbate PD symptoms (PIMPDs). Additionally, the most frequently prescribed PIMs and PIMPDs were investigated.
Results: PIMs were used at least once in 38.3% of 257,142 patients with PD. The mean number of PIM items used per patient was 2.61. The PIM usage ratio, corresponding to the proportion of the total amount of PIMs to all medications per patient, was 19.7%. The proportion of patients taking PIMs among all PD patients decreased significantly up to 2018 but then increased in 2019, while the PIM usage ratio increased steadily up to 2018 and then decreased in 2019. Excluding the representative PD medications, the most frequently prescribed PIM was amitriptyline. PIMPDs were also commonly used, including levosulpiride and haloperidol.
Conclusions: The prevalence and usage of PIMs were high in Korean PD patients during 2014-2019, and the utilization of PIMPDs persisted throughout this period. These findings can be used to develop evidence-based guidelines for robust polypharmacy management strategies to ensure the safety of medications used by PD patients.
期刊介绍:
The JCN aims to publish the cutting-edge research from around the world. The JCN covers clinical and translational research for physicians and researchers in the field of neurology. Encompassing the entire neurological diseases, our main focus is on the common disorders including stroke, epilepsy, Parkinson''s disease, dementia, multiple sclerosis, headache, and peripheral neuropathy. Any authors affiliated with an accredited biomedical institution may submit manuscripts of original articles, review articles, and letters to the editor. The JCN will allow clinical neurologists to enrich their knowledge of patient management, education, and clinical or experimental research, and hence their professionalism.